Loading company…
OxDX develops AI-based diagnostics to identify pathogens, including specific strains of respiratory viruses.
Founded in 2021, OxDX develops diagnostic technology that combines universal labeling and machine learning to identify viruses, bacteria, and other pathogens in clinical samples. Its technology can identify strains of COVID-19 and influenza. Based in Oxford, UK, the company raised GBP 2.6 million in pre-seed funding in February 2022 from Ahren Innovation Capital, IQ Capital Partners, and Science Creates Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in